Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627450 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL113727 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL10998172 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL236333 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL875411 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL125343 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL3454563 | 0.98 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1LPAR3 | |
| SCHEMBL20193278 | 0.89 | LPAR3 (0.48) | MEN1KMT2ATSHRLPAR3LPAR2 | |
| SCHEMBL8904061 | 0.89 | LPAR3 (0.48) | MEN1KMT2ATSHRLPAR3LPAR2 | |
| SCHEMBL20580710 | 0.89 | LPAR3 (0.48) | MEN1KMT2ATSHRLPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | IKARIA THERAPEUTICS LLC | 2015-01-01 | — | — | US | disclosed |
| US-8871189-B2 | MMP-targeted therapeutic and/or diagnostic nanocarriers | MALLINCKRODT LLC (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2785635-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | Mallinckrodt LLC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MALLINCKRODT INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013082389-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MALLINCKRODT INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | MALLINCKRODT LLC (US) | 2012-04-05 | — | — | US | disclosed |
| EP-1141056-B1 | BRANCHED/BLOCK COPOLYMERS FOR TREATMENT OF KERATINOUS SUBSTRATES | LUBRIZOL ADVANCED MAT INC (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-1290050-A1 | BRANCHED/BLOCK COPOLYMERS FOR TREATMENT OF KERATINOUS SUBSTRATES | Noveon IP Holdings Corp. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6410005-B1 | Branched/block copolymers for treatment of keratinous substrates | PMD HOLDINGS CORP. | 2002-06-25 | — | — | US | disclosed |
| WO-2001096429-A1 | BRANCHED/BLOCK COPOLYMERS FOR TREATMENT OF KERATINOUS SUBSTRATES | NOVEON IP HOLDINGS CORP. (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1141056-A1 | BRANCHED/BLOCK COPOLYMERS FOR TREATMENT OF KERATINOUS SUBSTRATES | The B.F. Goodrich Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040628-A1 | BRANCHED/BLOCK COPOLYMERS FOR TREATMENT OF KERATINOUS SUBSTRATES | THE B.F. GOODRICH COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | MEN1 2905/4885KMT2A 2837/4885TSHR 3349/4885 |
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | MEN1 2905/4885KMT2A 2837/4885TSHR 3349/4885 |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | EPHA2, ANXA6, SLC10A1 | MEN1 2323/4885KMT2A 1255/4885TSHR 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.